Skip to main content
S&P 5007,714.17+0.62%DOW51,007.41+0.16%NASDAQ27,176.17+1.13%BTC$85,491.00+1.74%ETH$2,703.21+0.61%GOLD$4,181.30-0.50%OIL$89.84-3.26%
Smart Investors Daily
SID Premium
MB

NASDAQ · MBRX

Moleculin Biotech, Inc.

Healthcare · Biotechnology

$0.50

Down-$0.00 (-0.73%)

Updated Oct 2, 2026, 2:43 PM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
6.01M
P/E ratio
-0.18
Dividend yield
0.00%
52-week range
$0.16 – $15.75
Volume
337.13K
Avg. volume
194.99K

Price performance · MBRX

MBRX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 1, 2026

MBRX closed at $0.50 after 20 trading sessions, down 25.42% for the selected period.

Last close
$0.50
Period change
-25.42%
Period low
$0.50
Period high
$0.83
Daily close
View OHLC price history
MBRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 1, 2026$0.505$0.5188$0.50$0.5038337.13K
Sep 30, 2026$0.5409$0.5498$0.492$0.5004720.15K
Sep 29, 2026$0.573$0.58$0.52$0.52641.66M
Sep 28, 2026$0.60$0.60$0.5401$0.569625.49K
Sep 25, 2026$0.551$0.6694$0.53$0.60162.62M
Sep 24, 2026$0.52$0.57$0.51$0.5669537.99K
Sep 23, 2026$0.58$0.6257$0.505$0.52791.82M
Sep 22, 2026$0.54$0.68$0.50$0.5655.88M
Sep 21, 2026$0.722$0.733$0.5004$0.52024.12M
Sep 18, 2026$0.7803$0.799$0.7501$0.7731466.34K
Sep 17, 2026$0.76$0.7963$0.74$0.78304.89K
Sep 16, 2026$0.76$0.7818$0.73$0.74273.85K
Sep 15, 2026$0.81$0.8175$0.7507$0.7516475.5K
Sep 14, 2026$0.75$0.82$0.75$0.7752719.2K
Sep 11, 2026$0.85$0.899$0.71$0.7151.93M
Sep 10, 2026$0.788$0.83$0.7735$0.8299533.63K
Sep 9, 2026$0.7711$0.8024$0.7506$0.765380.78K
Sep 8, 2026$0.735$0.80$0.724$0.7501736.84K
Sep 4, 2026$0.69$0.7375$0.68$0.7099775.6K
Sep 3, 2026$0.70$0.7299$0.6509$0.6755433.35K

Latest MBRX news

The latest Smart Investors Daily articles mentioning MBRX.

Stock researchCompany · Overview

MBRX research

Overview

Company profile and research snapshot.

Company profile

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$170.00
Implied upside
—
Analysts
9
MBRX recent ratings
DateFirmRatingTarget
Aug 28, 2026HC Wainwright & Co.Buy—
Mar 24, 2026HC Wainwright & Co.Buy—
Dec 11, 2025HC Wainwright & Co.Buy—
Sep 10, 2025HC Wainwright & Co.Buy—
Aug 27, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 25, 2026

Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR

Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin’s antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-mediated mechanism alongside its direct cytotoxic activity HOUSTON, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced new preclinical data indicating that the antitumor activity of its lead drug candidate, Annamycin (naxtarubicin), in pancreatic cancer is parti

Yahoo · Sep 23, 2026

Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040

Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commercial Opportunity HOUSTON, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the Mexican Patent Office has granted Patent No. 436849, further strengthening the Company's global intellectual property portfolio protecting its proprietary lung-targeted liposom

Yahoo · Sep 14, 2026

Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings

Presentations examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that new data on its lead drug candidate, Annamycin (naxtarubicin), will be presented at three scientific venues in September 2026, including the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer

Yahoo · Sep 11, 2026

Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand

Access the video webcast here HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here. The presentation, featuring Walter Klemp, Chairman and Chief Executive Officer of Moleculin, provides an overview of the Company as well as recent corporate and clinical developments. The on-d

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By